164 related articles for article (PubMed ID: 36632865)
1. Portal vein thrombosis as the presenting manifestation of JAK2 positive myeloproliferative neoplasm.
Jeon WJ; Mehta A; Hudson J; Castillo DR; Wang J; Nguyen A; Akhtari M
Am J Med Sci; 2023 May; 365(5):457-461. PubMed ID: 36632865
[TBL] [Abstract][Full Text] [Related]
2. [Portal vein thrombosis as the main symptom of unclassified JAK2-positive myeloproliferative neoplasm--case report].
Karakulska-Prystupiuk E; Gierej B; Paszkowska-Kowalewska M; Wilkowojska U; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Jul; 33(193):29-31. PubMed ID: 22993907
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
[TBL] [Abstract][Full Text] [Related]
4. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.
Waiswa M; Seremba E; Ocama P; Ddungu H; Opio K; Okello C; O'shea T; Verhovsek M; Mutyabule R
Afr Health Sci; 2014 Dec; 14(4):1069-73. PubMed ID: 25834519
[TBL] [Abstract][Full Text] [Related]
5. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
6. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.
Smalberg JH; Arends LR; Valla DC; Kiladjian JJ; Janssen HL; Leebeek FW
Blood; 2012 Dec; 120(25):4921-8. PubMed ID: 23043069
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study.
Mattar MM; Nassef S; El Husseiny NM; El Masry MR; Salah M; Morad MA; Gawad AA
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e425-e429. PubMed ID: 31229378
[TBL] [Abstract][Full Text] [Related]
8. Occult myeloproliferative neoplasms: not so occult any more.
Karam D; Iyer V; Agrawal B
BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28559287
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.
Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK
Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189
[TBL] [Abstract][Full Text] [Related]
10. JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis.
Foucar CE; Stein BL
JAMA; 2017 Jun; 317(21):2228-2229. PubMed ID: 28586872
[No Abstract] [Full Text] [Related]
11. Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies.
Kiladjian JJ; Cassinat B
Am J Hematol; 2023 May; 98(5):794-800. PubMed ID: 36869873
[TBL] [Abstract][Full Text] [Related]
12. Thrombotic risk factors in Chinese nonmalignant and noncirrhotic patients with portal vein thrombosis: an observational study with a systematic review of the literature.
Qi X; Wu F; He C; Fan D; Han G
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):77-83. PubMed ID: 25426980
[TBL] [Abstract][Full Text] [Related]
13. Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights.
Morsia E; Torre E; Martini F; Morè S; Poloni A; Olivieri A; Rupoli S
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338802
[TBL] [Abstract][Full Text] [Related]
14. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.
De Stefano V; Qi X; Betti S; Rossi E
Thromb Haemost; 2016 Jan; 115(2):240-9. PubMed ID: 26333846
[TBL] [Abstract][Full Text] [Related]
15. Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder.
Gianotti R; Charles H; Hymes K; Chandarana H; Sigal S
World J Gastroenterol; 2014 Oct; 20(39):14495-9. PubMed ID: 25339837
[TBL] [Abstract][Full Text] [Related]
16. [Recurrent deep vein thrombosis and myeloproliferative syndrom: emergence of JAK2 mutation five years after the initial event].
Salort A; Seinturier C; Molina L; Lévèque P; Imbert B; Pernod G
J Mal Vasc; 2014 May; 39(3):207-11. PubMed ID: 24721000
[TBL] [Abstract][Full Text] [Related]
17. Portal vein thrombosis as the first sign of a primary myeloproliferative disorder: diagnostic interest of the V617F JAK-2 mutation. A report of 2 cases.
de Suray N; Pranger D; Brenard R
Acta Gastroenterol Belg; 2008; 71(1):39-41. PubMed ID: 18396750
[TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
Magaz M; Alvarez-Larrán A; Colomer D; López-Guerra M; García-Criado MÁ; Mezzano G; Belmonte E; Olivas P; Soy G; Cervantes F; Darnell A; Ferrusquía-Acosta J; Baiges A; Turon F; Hernández-Gea V; García-Pagán JC
J Hepatol; 2021 Jan; 74(1):89-95. PubMed ID: 32679300
[TBL] [Abstract][Full Text] [Related]
19. Splanchnic vein thrombosis, the onset manifestation in JAK positive Chronic Myeloproliferative Disorders Neoplasms.
Vladareanu AM; Popov V; Bumbea H; Onisai M; Ilea A; Dobrea C; Miulescu M
J Med Life; 2011; 4(1):97-101. PubMed ID: 21505581
[TBL] [Abstract][Full Text] [Related]
20. JAK2 mutation: an aid in the diagnosis of occult myeloproliferative neoplasms in patients with major intraabdominal vein thrombosis and normal blood counts.
Sarid N; Eshel R; Rahamim E; Carmiel M; Kirgner I; Shpringer M; Trestman S; Marilus R; Perry C; Polliack A; Naparstek E; Herishanu Y
Isr Med Assoc J; 2013 Nov; 15(11):698-700. PubMed ID: 24511651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]